Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism

Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2008-06, Vol.22 (6), p.1191-1199
Hauptverfasser: Zhang, H, Trachootham, D, Lu, W, Carew, J, Giles, F J, Keating, M J, Arlinghaus, R B, Huang, P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1199
container_issue 6
container_start_page 1191
container_title Leukemia
container_volume 22
creator Zhang, H
Trachootham, D
Lu, W
Carew, J
Giles, F J
Keating, M J
Arlinghaus, R B
Huang, P
description Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant Bcr-Abl with 10 μ M PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.
doi_str_mv 10.1038/leu.2008.74
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2585768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A189833388</galeid><sourcerecordid>A189833388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</originalsourceid><addsrcrecordid>eNp1ks1v0zAYxiMEYmVw4o4sELtAiuOPfFyQpmqMSkVwKGfLcd40Hom92U5hR_5zHFptLRrywZLfn9_n8eM3SV5meJ5hWn7oYZwTjMt5wR4ls4wVeco5zx4nM1yWRZpXhJ0kz7y_wngq5k-Tk6ykJS84myW_L9oWVNBbQD9032uzQbZFlz3AFlTqwGsfpAlo8WWFFPS9Rz916NCaZnyJhjHIoK1B9S2SyMgwOtkjZYdrO5oGfbtYrhcodM6Omw45aOyvdIBGywANGkB10mg_PE-etLL38GK_nybfP12sF5_T1dfL5eJ8laqc4pACq6CuZK2KlrBCqow2TZU1qs4x1DXljLd5DTwvWkYk4TWXTQOSN7hhFc9JQU-Tj7u-12MdXSgwIboV104P0t0KK7U4rhjdiY3dCsJjVnkZG5ztGzh7M4IPYtB-ykQasKMXWcUpI3-V3vwDXtnRmfg4QXLGC1JGt5F6_V-KYE44PWy1kT0IbVobralJV5xnZVVSSsvJ2fwBKq4GBq2sgVbH86MLZwcXOpB96Lztx-kz_TH4bgcqZ7130N7llWExTZ-I0yem6RMFi_Srw4jv2f24ReDtHpBeyb510ijt7ziCGa04mWTf7zgfS2YD7j6bh3T_ANNi8F0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220525327</pqid></control><display><type>article</type><title>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Zhang, H ; Trachootham, D ; Lu, W ; Carew, J ; Giles, F J ; Keating, M J ; Arlinghaus, R B ; Huang, P</creator><creatorcontrib>Zhang, H ; Trachootham, D ; Lu, W ; Carew, J ; Giles, F J ; Keating, M J ; Arlinghaus, R B ; Huang, P</creatorcontrib><description>Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant Bcr-Abl with 10 μ M PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2008.74</identifier><identifier>PMID: 18385754</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Aldehyde Dehydrogenase - antagonists &amp; inhibitors ; Animals ; Anticarcinogenic Agents - pharmacology ; Antineoplastic Agents - pharmacology ; Antioxidants ; Antioxidants - pharmacology ; Apoptosis - drug effects ; BCR-ABL protein ; Benzamides ; Biological and medical sciences ; Cancer Research ; Cancer therapies ; Caspase 3 - metabolism ; Caspase-3 ; Cell activation ; Cell death ; Cells, Cultured ; Chromosome aberrations ; Chronic myeloid leukemia ; Critical Care Medicine ; Cytotoxicity ; Degradation ; Dosage and administration ; Drug resistance ; Drug Resistance, Neoplasm ; Drug therapy ; Enzyme Activation - drug effects ; Fusion protein ; Fusion Proteins, bcr-abl - genetics ; Fusion Proteins, bcr-abl - metabolism ; Gene mutations ; Genetic aspects ; Glutathione - metabolism ; Health aspects ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Imatinib Mesylate ; Immunoblotting ; Inhibitor drugs ; Intensive ; Internal Medicine ; Isothiocyanate ; Isothiocyanates - therapeutic use ; Kinases ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical genetics ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Mice ; Mutation ; Mutation - genetics ; Myeloid leukemia ; Oncology ; original-article ; Oxidation-Reduction ; Oxidative stress ; Piperazines - pharmacology ; Precursor Cells, B-Lymphoid - drug effects ; Precursor Cells, B-Lymphoid - metabolism ; Proteasomes ; Protein-tyrosine kinase ; Protein-Tyrosine Kinases - antagonists &amp; inhibitors ; Proteins ; Pyrimidines - pharmacology ; Reactive Oxygen Species - metabolism ; Targeted cancer therapy ; Thiocyanates ; Tumor cell lines</subject><ispartof>Leukemia, 2008-06, Vol.22 (6), p.1191-1199</ispartof><rights>Springer Nature Limited 2008</rights><rights>2008 INIST-CNRS</rights><rights>COPYRIGHT 2008 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2008</rights><rights>Nature Publishing Group 2008.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</citedby><cites>FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/leu.2008.74$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/leu.2008.74$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20439528$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18385754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Trachootham, D</creatorcontrib><creatorcontrib>Lu, W</creatorcontrib><creatorcontrib>Carew, J</creatorcontrib><creatorcontrib>Giles, F J</creatorcontrib><creatorcontrib>Keating, M J</creatorcontrib><creatorcontrib>Arlinghaus, R B</creatorcontrib><creatorcontrib>Huang, P</creatorcontrib><title>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant Bcr-Abl with 10 μ M PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.</description><subject>Aldehyde Dehydrogenase - antagonists &amp; inhibitors</subject><subject>Animals</subject><subject>Anticarcinogenic Agents - pharmacology</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antioxidants</subject><subject>Antioxidants - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>BCR-ABL protein</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Caspase 3 - metabolism</subject><subject>Caspase-3</subject><subject>Cell activation</subject><subject>Cell death</subject><subject>Cells, Cultured</subject><subject>Chromosome aberrations</subject><subject>Chronic myeloid leukemia</subject><subject>Critical Care Medicine</subject><subject>Cytotoxicity</subject><subject>Degradation</subject><subject>Dosage and administration</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug therapy</subject><subject>Enzyme Activation - drug effects</subject><subject>Fusion protein</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Fusion Proteins, bcr-abl - metabolism</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>Glutathione - metabolism</subject><subject>Health aspects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Immunoblotting</subject><subject>Inhibitor drugs</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Isothiocyanate</subject><subject>Isothiocyanates - therapeutic use</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mice</subject><subject>Mutation</subject><subject>Mutation - genetics</subject><subject>Myeloid leukemia</subject><subject>Oncology</subject><subject>original-article</subject><subject>Oxidation-Reduction</subject><subject>Oxidative stress</subject><subject>Piperazines - pharmacology</subject><subject>Precursor Cells, B-Lymphoid - drug effects</subject><subject>Precursor Cells, B-Lymphoid - metabolism</subject><subject>Proteasomes</subject><subject>Protein-tyrosine kinase</subject><subject>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</subject><subject>Proteins</subject><subject>Pyrimidines - pharmacology</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Targeted cancer therapy</subject><subject>Thiocyanates</subject><subject>Tumor cell lines</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1ks1v0zAYxiMEYmVw4o4sELtAiuOPfFyQpmqMSkVwKGfLcd40Hom92U5hR_5zHFptLRrywZLfn9_n8eM3SV5meJ5hWn7oYZwTjMt5wR4ls4wVeco5zx4nM1yWRZpXhJ0kz7y_wngq5k-Tk6ykJS84myW_L9oWVNBbQD9032uzQbZFlz3AFlTqwGsfpAlo8WWFFPS9Rz916NCaZnyJhjHIoK1B9S2SyMgwOtkjZYdrO5oGfbtYrhcodM6Omw45aOyvdIBGywANGkB10mg_PE-etLL38GK_nybfP12sF5_T1dfL5eJ8laqc4pACq6CuZK2KlrBCqow2TZU1qs4x1DXljLd5DTwvWkYk4TWXTQOSN7hhFc9JQU-Tj7u-12MdXSgwIboV104P0t0KK7U4rhjdiY3dCsJjVnkZG5ztGzh7M4IPYtB-ykQasKMXWcUpI3-V3vwDXtnRmfg4QXLGC1JGt5F6_V-KYE44PWy1kT0IbVobralJV5xnZVVSSsvJ2fwBKq4GBq2sgVbH86MLZwcXOpB96Lztx-kz_TH4bgcqZ7130N7llWExTZ-I0yem6RMFi_Srw4jv2f24ReDtHpBeyb510ijt7ziCGa04mWTf7zgfS2YD7j6bh3T_ANNi8F0</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Zhang, H</creator><creator>Trachootham, D</creator><creator>Lu, W</creator><creator>Carew, J</creator><creator>Giles, F J</creator><creator>Keating, M J</creator><creator>Arlinghaus, R B</creator><creator>Huang, P</creator><general>Nature Publishing Group UK</general><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>20080601</creationdate><title>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</title><author>Zhang, H ; Trachootham, D ; Lu, W ; Carew, J ; Giles, F J ; Keating, M J ; Arlinghaus, R B ; Huang, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aldehyde Dehydrogenase - antagonists &amp; inhibitors</topic><topic>Animals</topic><topic>Anticarcinogenic Agents - pharmacology</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antioxidants</topic><topic>Antioxidants - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>BCR-ABL protein</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Caspase 3 - metabolism</topic><topic>Caspase-3</topic><topic>Cell activation</topic><topic>Cell death</topic><topic>Cells, Cultured</topic><topic>Chromosome aberrations</topic><topic>Chronic myeloid leukemia</topic><topic>Critical Care Medicine</topic><topic>Cytotoxicity</topic><topic>Degradation</topic><topic>Dosage and administration</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug therapy</topic><topic>Enzyme Activation - drug effects</topic><topic>Fusion protein</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Fusion Proteins, bcr-abl - metabolism</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>Glutathione - metabolism</topic><topic>Health aspects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Immunoblotting</topic><topic>Inhibitor drugs</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Isothiocyanate</topic><topic>Isothiocyanates - therapeutic use</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mice</topic><topic>Mutation</topic><topic>Mutation - genetics</topic><topic>Myeloid leukemia</topic><topic>Oncology</topic><topic>original-article</topic><topic>Oxidation-Reduction</topic><topic>Oxidative stress</topic><topic>Piperazines - pharmacology</topic><topic>Precursor Cells, B-Lymphoid - drug effects</topic><topic>Precursor Cells, B-Lymphoid - metabolism</topic><topic>Proteasomes</topic><topic>Protein-tyrosine kinase</topic><topic>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</topic><topic>Proteins</topic><topic>Pyrimidines - pharmacology</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Targeted cancer therapy</topic><topic>Thiocyanates</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Trachootham, D</creatorcontrib><creatorcontrib>Lu, W</creatorcontrib><creatorcontrib>Carew, J</creatorcontrib><creatorcontrib>Giles, F J</creatorcontrib><creatorcontrib>Keating, M J</creatorcontrib><creatorcontrib>Arlinghaus, R B</creatorcontrib><creatorcontrib>Huang, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, H</au><au>Trachootham, D</au><au>Lu, W</au><au>Carew, J</au><au>Giles, F J</au><au>Keating, M J</au><au>Arlinghaus, R B</au><au>Huang, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2008-06-01</date><risdate>2008</risdate><volume>22</volume><issue>6</issue><spage>1191</spage><epage>1199</epage><pages>1191-1199</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant Bcr-Abl with 10 μ M PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>18385754</pmid><doi>10.1038/leu.2008.74</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-6924
ispartof Leukemia, 2008-06, Vol.22 (6), p.1191-1199
issn 0887-6924
1476-5551
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2585768
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; SpringerLink Journals - AutoHoldings
subjects Aldehyde Dehydrogenase - antagonists & inhibitors
Animals
Anticarcinogenic Agents - pharmacology
Antineoplastic Agents - pharmacology
Antioxidants
Antioxidants - pharmacology
Apoptosis - drug effects
BCR-ABL protein
Benzamides
Biological and medical sciences
Cancer Research
Cancer therapies
Caspase 3 - metabolism
Caspase-3
Cell activation
Cell death
Cells, Cultured
Chromosome aberrations
Chronic myeloid leukemia
Critical Care Medicine
Cytotoxicity
Degradation
Dosage and administration
Drug resistance
Drug Resistance, Neoplasm
Drug therapy
Enzyme Activation - drug effects
Fusion protein
Fusion Proteins, bcr-abl - genetics
Fusion Proteins, bcr-abl - metabolism
Gene mutations
Genetic aspects
Glutathione - metabolism
Health aspects
Hematologic and hematopoietic diseases
Hematology
Humans
Imatinib Mesylate
Immunoblotting
Inhibitor drugs
Intensive
Internal Medicine
Isothiocyanate
Isothiocyanates - therapeutic use
Kinases
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical genetics
Medical sciences
Medicine
Medicine & Public Health
Mice
Mutation
Mutation - genetics
Myeloid leukemia
Oncology
original-article
Oxidation-Reduction
Oxidative stress
Piperazines - pharmacology
Precursor Cells, B-Lymphoid - drug effects
Precursor Cells, B-Lymphoid - metabolism
Proteasomes
Protein-tyrosine kinase
Protein-Tyrosine Kinases - antagonists & inhibitors
Proteins
Pyrimidines - pharmacology
Reactive Oxygen Species - metabolism
Targeted cancer therapy
Thiocyanates
Tumor cell lines
title Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T16%3A15%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20killing%20of%20Gleevec-resistant%20CML%20cells%20with%20T315I%20mutation%20by%20a%20natural%20compound%20PEITC%20through%20redox-mediated%20mechanism&rft.jtitle=Leukemia&rft.au=Zhang,%20H&rft.date=2008-06-01&rft.volume=22&rft.issue=6&rft.spage=1191&rft.epage=1199&rft.pages=1191-1199&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/leu.2008.74&rft_dat=%3Cgale_pubme%3EA189833388%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220525327&rft_id=info:pmid/18385754&rft_galeid=A189833388&rfr_iscdi=true